RCT | The addition of Olanzapine to a triple antiemetic regimen effectively prevents nausea and vomiting during highly emetogenic chemotherapy.

A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study) – eClinicalMedicine

Related:

RCT: Olanzapine may improve the control of vomiting in the delayed phase in children receiving highly emetogenic chemotherapy.

Randomized, open-label trial: Olanzapine seems effective for the prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy

Randomized Trial: Olanzapine Plus Standard Antiemetic Therapy for the Prevention of Chemotherapy-induced Nausea and Vomiting